3 months of tirzepatide Compounded GLP-1/GIP (3 Month) – Verge 20 months- before and after

Mood or behaviour changes low incidence, with only 1.2% of total safety reports for GLP-1 agonists

Wrapping vials in aluminum foil or storing them in an opaque container addresses this concern with minimal effort

Tirzepatide takes the concept further

Access is currently limited to approved clinical trials

And hepatic steatosis resolved in greater than 85% of participants with retatrutide 8 mg and 12 mg at week 48. The safety profile of retatrutide in the NAFLD subset was similar to that in the obesity population, and no hepatotoxicity signals in obesity or NAFLD was seen through week 48

If you find the taste of ReconstruXion to be too bitter, simply mix in more water